Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.

Autor: Willemijn S M E Theelen, Thomas Kuilman, Katja Schulze, Wei Zou, Oscar Krijgsman, Dennis D G C Peters, Sten Cornelissen, Kim Monkhorst, Pranamee Sarma, Teiko Sumiyoshi, Lukas C Amler, Stefan M Willems, Johannes L G Blaauwgeers, Carel J M van Noesel, Daniel S Peeper, Michel M van den Heuvel, Marcin Kowanetz

Publikováno v: PLoS ONE, Vol 14, Iss 5, p e0216864 (2019)

BackgroundIn non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both TC and tumor-infiltrating immune cells (IC) is currently the most used biomarker in cancer immunotherapy. However, the mechanisms involved in PD-L1 r

Externí odkaz: https://doaj.org/article/71ec07804c5045b0afac420650e42855

IL-5-producing CD4

Autor: Olga S, Blomberg, Lorenzo, Spagnuolo, Hannah, Garner, Leonie, Voorwerk, Olga I, Isaeva, Ewald, van Dyk, Noor, Bakker, Myriam, Chalabi, Chris, Klaver, Maxime, Duijst, Kelly, Kersten, Marieke, Brüggemann, Dorien, Pastoors, Cheei-Sing, Hau, Kim, Vrijland, Elisabeth A M, Raeven, Daphne, Kaldenbach, Kevin, Kos, Inna S, Afonina, Paulien, Kaptein, Louisa, Hoes, Willemijn S M E, Theelen, Paul, Baas, Emile E, Voest, Rudi, Beyaert, Daniela S, Thommen, Lodewyk F A, Wessels, Karin E, de Visser, Marleen, Kok

Publikováno v: Cancer cell.

Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::858404ab7e5b5d36c2dd670afa56af35
https://pubmed.ncbi.nlm.nih.gov/36525971

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Autor: Ferdinandos Skoulidis, George R. Simon, Idris Bahce, Paul Baas, Joachim G.J.V. Aerts, Quynh Nhu Nguyen, Anna Larissa N. Niemeijer, Steven H. Lin, Dawei Chen, Kewen He, Heike Peulen, Brian P. Hobbs, Roshal R. Patel, Vivek Verma, James W. Welsh, Willemijn S. M. E. Theelen, Joe Y. Chang, John V. Heymach, Patricia M. de Groot, Nathan Comeaux

Publikováno v: The Lancet Respiratory Medicine, 9(5), 467-475. Elsevier Limited
The Lancet Respiratory Medicine, 9(5), 467-475. Elsevier Ltd.
Theelen, W S M E, Chen, D, Verma, V, Hobbs, B P, Peulen, H M U, Aerts, J G J V, Bahce, I, Niemeijer, A L N, Chang, J Y, de Groot, P M, Nguyen, Q-N, Comeaux, N I, Simon, G R, Skoulidis, F, Lin, S H, He, K, Patel, R, Heymach, J, Baas, P & Welsh, J W 2021, ' Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials ', The Lancet Respiratory Medicine, vol. 9, no. 5, pp. 467-475 . https://doi.org/10.1016/S2213-2600(20)30391-X
The Lancet Respiratory Medicine, 9(5), 467-475. ELSEVIER SCI LTD

Findings Overall, 148 patients were included in the pooled analysis, 76 of whom had been assigned pembrolizumab and 72 who had been assigned pembrolizumab plus radiotherapy. Median follow-up for all patients was 33 months (IQR 32?4?33?6). 124 (84%) o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcdadd3a2e31d7df46de6d2585dcdbe9
https://research.vumc.nl/en/publications/56927a12-23a7-4f97-a281-de8001690bb8

Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath

Autor: Vincent van der Noort, Peter J. Sterk, Marguerite Wolf-Lansdorf, Robert D Schouten, Paul Baas, S.H. Muller, Kim Monkhorst, Willemijn S. M. E. Theelen, R. de Vries, Mirte Muller, Karlijn Hummelink, A.H. Maitland-van der Zee, J. W. F. Dagelet, M. van den Heuvel

Publikováno v: Annals of Oncology, 30, 1660-1666
Annals of oncology, 30(10), 1660-1666. Oxford University Press
Annals of Oncology, 30, 10, pp. 1660-1666

Contains fulltext : 215691.pdf (Publisher’s version ) (Closed access) BACKGROUND: Immune checkpoint inhibitors have improved survival outcome of advanced non-small-cell lung cancer (NSCLC). However, most patients do not benefit. Therefore, biomarke

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e48805022776c5c8c542922f4afc753f
https://doi.org/10.1093/annonc/mdz279

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Autor: G. Laus, Angelo Delmonte, Vassiliki A. Papadimitrakopoulou, Sang We Kim, Willemijn S. M. E. Theelen, Y-L. Wu, Tony Mok, Yuri Rukazenkov, Suresh S. Ramalingam, Helen Mann, Hiroaki Akamatsu, Myung-Ju Ahn, Yong He, Martin Sebastian, Janessa Laskin, Ji Youn Han, Thomas John, Frances A. Shepherd, Wu Chou Su, M. Miranda

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 31(11)

In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0d038c290468424793940d06b82cc7b
https://pubmed.ncbi.nlm.nih.gov/32861806